4.5 Letter

Losartan as therapy for recessive dystrophic epidermolysis bullosa: Report of three cases

Related references

Note: Only part of the references are listed.
Letter Dermatology

Losartan for treatment of epidermolysis bullosa: A new perspective

Jouni Uitto et al.

DERMATOLOGIC THERAPY (2021)

Review Dermatology

Investigational Treatments for Epidermolysis Bullosa

Ping-Chen Hou et al.

Summary: Epidermolysis bullosa is a rare inherited blistering skin disorder characterized by skin fragility since birth, with treatment mainly focusing on wound care and patient symptoms. Recent therapeutic advances such as gene therapies, cell-based therapies, and drug repurposing approaches offer new hope for better patient care and improved clinical management.

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2021)

Article Medicine, Research & Experimental

Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms

Alexander Nystroem et al.

EMBO MOLECULAR MEDICINE (2015)

Article Urology & Nephrology

A Randomized, Open-Label, Dose-Response Study of Losartan in Hypertensive Children

Nicholas J. A. Webb et al.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)

Article Urology & Nephrology

Randomized, Double-Blind, Controlled Study of Losartan in Children with Proteinuria

Nicholas J. A. Webb et al.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)

Review Dermatology

Extracutaneous manifestations and complications of inherited epidermolysis bullosa Part I. Epithelial associated tissues

Jo-David Fine et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2009)